PTI 110

Drug Profile

PTI 110

Alternative Names: AA-amyloidosis therapeutic - ProteoTech; PTI-110; Systebryl

Latest Information Update: 14 Jan 2015

Price : $50

At a glance

  • Originator ProteoTech
  • Class Small molecules
  • Mechanism of Action Amyloid fibril protein AL inhibitors; Amyloid inhibitors; Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Amyloidosis

Most Recent Events

  • 12 Jan 2015 PTI 110 receives Orphan Drug status for Amyloidosis in USA
  • 12 May 2014 Clinical development is ongoing in USA
  • 23 Apr 2012 ProteoTech completes a phase I trial in Amyloidosis in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top